Related Experiment Videos
Clofibrate and the development of rats
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement
|January 1, 1980
Summary
Clofibrate (CPIB) exposure during pregnancy and lactation in rats reduced offspring birth weight and increased perinatal mortality. Liver weight also increased but normalized after treatment cessation.
Area of Science:
- Toxicology
- Developmental Biology
- Pharmacology
Background:
- Clofibrate (CPIB) is a lipid-lowering drug with known effects on liver metabolism.
- Understanding the peri- and postnatal developmental impacts of drug exposure is crucial for assessing safety.
Purpose of the Study:
- To investigate the effects of maternal Clofibrate (CPIB) administration on the development of Wistar-H-Riop rat offspring.
- To determine the timing and duration of CPIB exposure critical for observed effects.
Main Methods:
- Pregnant Wistar-H-Riop rats were administered 150 mg/kg/day of CPIB from day 16 of gestation to day 22 postpartum.
- Offspring were assessed for birth weight, liver weight, and perinatal mortality.
- Exposure timing varied, including late pregnancy and different lactation periods.
Main Results:
- CPIB exposure significantly decreased offspring birth weight.
- A notable increase in liver weight was observed in newborn rats post-treatment.
- Perinatal mortality rates were elevated in the CPIB-exposed group.
- The increased liver weight was transient, normalizing within one week after cessation of CPIB treatment.
Conclusions:
- Maternal CPIB exposure during critical peri- and postnatal periods adversely affects offspring development, including reduced birth weight and increased mortality.
- While CPIB induces temporary liver weight gain in neonates, this effect is reversible upon drug withdrawal.